CorMedix Inc.

8.06+0.1300+1.64%Vol 289.87K1Y Perf 95.90%
Apr 22nd, 2021 16:00 DELAYED
BID8.02 ASK8.07
Open7.95 Previous Close7.93
Pre-Market- After-Market-
 - -%  - -
Target Price
20.70 
Analyst Rating
Strong Buy 1.00
Potential %
156.82 
Finscreener Ranking
★★★★+     58.58
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★+     54.39
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★     54.78
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap306.47M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
29.94 
Earnings Date
10th May 2021

Today's Price Range

7.668.32

52W Range

3.4718.80

5 Year PE Ratio Range

-3.20-3.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
3.07%
1 Month
-13.80%
3 Months
-6.71%
6 Months
37.78%
1 Year
95.90%
3 Years
667.62%
5 Years
-60.68%
10 Years
-8.41%

TickerPriceChg.Chg.%
CRMD8.060.13001.64
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Financial StrengthValueIndustryS&P 500US Markets
11.10
11.60
0.02
0.02
-817.50
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
14.40
-12 664.80
-12 634.10
-9 243.70
-
RevenueValueIndustryS&P 500US Markets
165.18K
0.00
-11.51
4.03
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.23-0.1917.39
Q03 2020-0.26-0.2215.38
Q02 2020-0.24-0.1441.67
Q01 2020-0.23-0.218.70
Q04 2019-0.24-0.2112.50
Q03 2019-0.25-0.2212.00
Q02 2019-0.22-0.24-9.09
Q01 2019-0.29-0.2224.14
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.1825.00Positive
6/2021 QR-0.1917.39Positive
12/2021 FY-0.834.60Positive
12/2022 FY-0.94-176.47Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.18
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume289.87K
Shares Outstanding38.02M
Trades Count2.88K
Dollar Volume18.17M
Avg. Volume1.16M
Avg. Weekly Volume435.60K
Avg. Monthly Volume558.95K
Avg. Quarterly Volume1.32M

CorMedix Inc. (AMEX: CRMD) stock closed at 8.06 per share at the end of the most recent trading day (a 1.64% change compared to the prior day closing price) with a volume of 290.61K shares and market capitalization of 306.47M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 30 people. CorMedix Inc. CEO is Khoso Baluch.

The one-year performance of CorMedix Inc. stock is 95.9%, while year-to-date (YTD) performance is 8.48%. CRMD stock has a five-year performance of -60.68%. Its 52-week range is between 3.47 and 18.8, which gives CRMD stock a 52-week price range ratio of 29.94%

CorMedix Inc. currently has a PE ratio of -10.30, a price-to-book (PB) ratio of 6.72, a price-to-sale (PS) ratio of 1 800.19, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -54.12%, a ROC of -66.44% and a ROE of -62.97%. The company’s profit margin is -%, its EBITDA margin is -12 634.10%, and its revenue ttm is $165.18 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from CorMedix Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.18 for the next earnings report. CorMedix Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for CorMedix Inc. is Strong Buy (1), with a target price of $20.7, which is +156.82% compared to the current price. The earnings rating for CorMedix Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CorMedix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CorMedix Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 29.13, ATR14 : 1.12, CCI20 : -72.03, Chaikin Money Flow : 0.00, MACD : -1.16, Money Flow Index : 16.92, ROC : -14.44, RSI : 34.57, STOCH (14,3) : 27.39, STOCH RSI : 1.00, UO : 44.19, Williams %R : -72.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CorMedix Inc. in the last 12-months were: Alan W. Dunton (Buy at a value of $39 500), John L. Armstrong (Buy at a value of $72 650), Khoso Baluch (Buy at a value of $19 985), Matt David (Buy at a value of $4 681), Mehmood Khan (Buy at a value of $442 701), Myron Kaplan (Buy at a value of $264 678), Phoebe Mounts (Buy at a value of $10 176), Steven W. Lefkowitz (Buy at a value of $22 816)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CorMedix Inc.

Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution or the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology. The Neutrolin product is designed to target unmet medical need.

CEO: Khoso Baluch

Telephone: +1 908 517-9500

Address: 400 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 30

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

48%52%

News

Stocktwits